drugset / Trial / NCT01064037

A Phase IIb Study to Investigate the Efficacy and Tolerability of Cinaciguat (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF)

NCT01064037 ↗

Phase 2 Terminated 62 enrolled Bayer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A placebo controlled, double-blind and randomized study to assess different doses of a new drug (BAY58-2667) given intravenously, to evaluate if it is safe and can help to improve the well-being of patients with acute decompensated heart failure.

Timeline

Start
2010-04
Primary completion
2011-02
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Cinaciguat Small molecule 50 ug Intravenous
Subject Cinaciguat Small molecule 100 ug Intravenous
Subject Cinaciguat Small molecule 150 ug Intravenous

Indications